XORTX Moving to the Next Phase
New 25-page Update Equity Research Report on XORTX, with a Buy rating and one-year price target of $26.00/share. The Company has two potential late-stage drugs in development focused on kidney diseases with one drug that could be approved within the next 18 months and the other drug that could have an orphan drug indication on the market in 2025. [more]
